IGF1R and cancer: In many cancers, these alternative RTKs including MET, IGF1R, FGFR and EphA2 become activated or amplified in order to maintain the signals for cell survival and/or proliferation in common downstream pathways, thus nullifying the inhibition of EGFR kinase [6-10].